1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MERUS LABS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 23,800 | +0,85 % | MPH Health Care Aktie: Finanzberichte neutral bewertet | Der Gesundheitsinvestor MPH Health Care AG verzeichnete am 21. Februar 2025 einen marginalen Kursrückgang von 0,43 Prozent auf 23,20 EUR. Die Aktie des Berliner Unternehmens zeigt sich dennoch in einer... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 5,926 | +8,50 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| AMARIN | 0,520 | +5,26 % | Amarin Corporation plc: Amarin Marks Key Milestone for VASCEPA/VAZKEPA (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol ... | -- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,184 | +7,44 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL | - Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 304,10 | +1,43 % | Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.8% Following Insider Selling | ||
| CATALYST PHARMACEUTICALS | 21,360 | +0,28 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 57,50 | +2,68 % | ANI Pharmaceuticals Receives FDA Approval For Purified Cortrophin Gel Prefilled Syringe | WASHINGTON (dpa-AFX) - ANI Pharmaceuticals Inc. (ANIP) announced that the U.S. Food and Drug Administration approved Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line | Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| TITAN PHARMACEUTICALS | 0,001 | -100,00 % | Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq | NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing... ► Artikel lesen | |
| BLUM HOLDINGS | - | - | Blum Holdings: Blüm Holdings, Inc. Announces Strategic Financing and Intended Acquisitions | DOWNEY, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Blum Holdings, Inc. (OTCQB: BLMH) (the "Company," "Blüm", "Blüm Holdings," "we" or "us"), a California-based cannabis operator, today announced the... ► Artikel lesen | |
| BMP PHARMA TRADING | 4,900 | +4,26 % | PTA-News: B.M.P. Pharma Trading AG: Steigerung der Rentabilität im 1. Halbjahr 2024 - Rentabilitätsanstieg EBIT um 15,5% | DJ PTA-News: B.M.P. Pharma Trading AG: Steigerung der Rentabilität im 1. Halbjahr 2024 - Rentabilitätsanstieg EBIT um 15,5%
Unternehmensmitteilung für den Kapitalmarkt
Norderstedt (pta/02.10.2024/16:48)... ► Artikel lesen | |
| THERIVA BIOLOGICS | 1,360 | 0,00 % | Theriva Biologics, Inc.: Theriva Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer | ROCKVILLE, Md., Dec. 05, 2024the completion of target enrollment into the multinational VIRAGE Phase 2b clinical study evaluating intravenous VCN-01 in combination with gemcitabine/nab-paclitaxel as... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 0,830 | -1,19 % | Kazia Therapeutics Limited: Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA | SYDNEY, Dec. 31, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,075 | +7,14 % | Allergy Therapeutics - New Executive Long Term Incentive Awards | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - 8-K, Current Report |
Das Unternehmen MERUS LABS INTERNATIONAL INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MERUS LABS INTERNATIONAL INC finden Sie auf Wallstreet Online.
